4. Issues of Ethnopharmacology in HIV Management
Differences in Drug Resistance Patterns
Another important concern that is applicable among patients with HIV-1 from different clades is that in patients infected with non-clade-B HIV-1, different patterns of antiretroviral resistance can emerge compared with those that occur in clade-B HIV-1. For example, Chaplin and colleagues found significant variations in reverse transcriptase (RT) mutations in non-B subtype infections among 338 Nigerian patients.
This suggests that clinicians should exercise care in selecting both initial and subsequent RT inhibitors in managing patients infected with such non-B subtypes. Munerato and colleagues reported that, among 2,472 Brazilian patients resistance mutations to protease inhibitors and nucleoside reverse transcriptase inhibitors were less common in subtype C viruses, whereas nonnucleoside reverse transcriptase inhibitor resistance mutations were less common in subtype F viruses. [Chaplin 2011, Munerato 2010]
Findings such as these underline how important it is that clinicians invest effort into understanding patients’ racial, ethnic, and geographic background so as to determine whether they may have HIV disease from a subtype that differs from the subtype B infections occurring in most American and West European HIV-positive persons. This means that clinicians must be aware that, in patients infected with different HIV clades, the well-recognized patterns of antiretroviral resistance that practitioners know how to anticipate and to manage antiretroviral therapy accordingly may be different. For example, clinicians may use this information to choose the sequencing of antiretroviral agents such as NNRTIs and integrase inhibitors.